Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $123.56.

BPMC has been the topic of several analyst reports. Stephens reissued an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th.

Insider Buying and Selling

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,000 shares of Blueprint Medicines stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the sale, the director now owns 157,557 shares in the company, valued at $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ariel Hurley sold 1,819 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the transaction, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Blueprint Medicines

Institutional investors have recently modified their holdings of the business. Quarry LP acquired a new stake in Blueprint Medicines in the third quarter valued at $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines during the 4th quarter worth about $51,000. Covestor Ltd lifted its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 403 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in Blueprint Medicines in the fourth quarter valued at approximately $88,000. Finally, Van ECK Associates Corp increased its stake in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after purchasing an additional 363 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of BPMC traded down $0.27 during mid-day trading on Thursday, reaching $114.05. The stock had a trading volume of 1,299,150 shares, compared to its average volume of 935,755. The business has a fifty day moving average of $97.07 and a 200 day moving average of $95.27. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The firm has a market cap of $7.25 billion, a price-to-earnings ratio of -54.05 and a beta of 0.61. Blueprint Medicines has a 12 month low of $72.24 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same quarter in the previous year, the firm earned ($2.20) earnings per share. The company's quarterly revenue was up 126.5% compared to the same quarter last year. Equities analysts predict that Blueprint Medicines will post -3.67 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.